Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

PURPOSE: This phase II study investigated whether durvalumab/tremelimumab with proton therapy improves the objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) in heavily treated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) patients. MATE...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hana, Park, Sehhoon, Jung, Hyun Ae, Lee, Se-Hoon, Park, Keunchil, Ahn, Yong Chan, Oh, Dongryul, Ahn, Myung-Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582547/
https://www.ncbi.nlm.nih.gov/pubmed/37202212
http://dx.doi.org/10.4143/crt.2023.502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582547/
https://www.ncbi.nlm.nih.gov/pubmed/37202212
http://dx.doi.org/10.4143/crt.2023.502

Ejemplares similares